Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C25H21F3N4O3S
CAS Number:
Molecular Weight:
514.52
MDL number:
NACRES:
NA.28
SMILES string
FC(F)(C1=NC(C2=CC(C(NCC3(C4=NC(C5=CC=CC=C5)=CS4)CCOCC3)=O)=CC=C2)=NO1)F
assay
≥98% (HPLC)
form
powder
color
white to yellow-orange
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Potent and type IIa-selective histone deacetylases (HDAC4/5/7/9) inhibitor in vitro and in vivo.
TMP269 is a potent and type IIa-selective histone deacetylases (HDACs) inhibitor (HDAC4/5/7/9 Ki = 126/80/36/19 nM, IC50 = 157/97/43/23 nM; HDAC6/8 IC50 = 8.2/4.2 μM, HADC1/2/3/10/11 IC50 >100 μM) with an active site zinc-targeting trifluoromethyloxadiazole (TFMO). TMP269 inhibits the growth of AsPC-1 by upregulating FOXO3a expression and displays in vivo therapeutic efficacy in animal models of acute kidney injury (50 mg/kg via i.p. in mice) and cerebral ischemia/reperfusion injury (1-16 mg/kg via i.p. in rats).
TMP269 is a potent and type IIa-selective histone deacetylases (HDACs) inhibitor (HDAC4/5/7/9 Ki = 126/80/36/19 nM, IC50 = 157/97/43/23 nM; HDAC6/8 IC50 = 8.2/4.2 μM, HADC1/2/3/10/11 IC50 >100 μM) with an active site zinc-targeting trifluoromethyloxadiazole (TFMO). TMP269 inhibits the growth of AsPC-1 by upregulating FOXO3a expression and displays in vivo therapeutic efficacy in animal models of acute kidney injury (50 mg/kg via i.p. in mice) and cerebral ischemia/reperfusion injury (1-16 mg/kg via i.p. in rats).
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service